Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: patron_anejo_por_favor who wrote (100820)	5/9/2001 3:58:41 AM
From: NOW	Respond to of 436258

I concur fully with this sentiment; sadly the public is terribly decieved on this matter.

To: patron_anejo_por_favor who wrote (100820)	5/9/2001 8:01:43 AM
From: Ilaine	Respond to of 436258

>>Utilization of newer drugs is not necessarily a function of superior therapeutic effect and/or a safer side effect profile.<< This statement is far too sweeping, IMO. It depends on the drug, and the disease. The advances in molecular biology, cellular biology, immunology, genetics, over the past decade or two are nothing short of astonishing. I won't go into detail about the stuff I take for my RA - we've discussed it before - vastly superior to what was available a couple of years ago. Another disease - AIDS - used to be a death sentence. New chemotherapy drugs for cancers that couldn't be cured. New antibiotics for drug-resistant strains of bacteria. Sure, they cost more than penicillin, but penicillin doesn't work anymore, not on these bugs. Prozac is better than MAOs. Viagra - no alternative. They do have us by the short and curlies when it comes to price, though.-ng-